A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs PRO 140 (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Registrational; Therapeutic Use
  • Sponsors CytoDyn
  • Most Recent Events

    • 11 Apr 2018 According to a CytoDyn Inc. media release, company will Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018
    • 09 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Aug 2018.
    • 09 Mar 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top